RxDoctor Payments Data

Eboni Murraine

Family · Huntsville, ALNPI 1275170565

Payments from drug & device makers

$8,467in general payments, 2019–2025

Across 490 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$890
  • Bayer$798
  • GSK$754
  • AbbVie$479
  • Sanofi-aventis U.S. LLC$338
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$8,467100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,467 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$79,163
FarxigaDapagliflozin Propanediol52$49,752
JardianceEmpagliflozin25$32,178
JanuviaSitagliptin Phosphate27$32,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$30,231
RybelsusSemaglutide18$29,620
JanumetSitagliptin Phos/Metformin Hcl21$19,546
LinzessLinaclotide12$19,375
Soliqua 100-33Insulin Glargine/Lixisenatide17$15,037
MounjaroTirzepatide13$14,122
EliquisApixaban11$14,117
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$13,843
Tresiba Flextouch U-200Insulin Degludec17$13,203
Clonidine26$5,878
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$4,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,973$108,78273 claims
MerckJanuvia, Janumet$56$51,54848 claims
AstraZenecaFarxiga$890$49,75252 claims
Boehringer IngelheimJardiance$299$32,17825 claims
GSKTrelegy Ellipta$754$30,23137 claims
AbbVieLinzess, Synthroid$479$20,31824 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$338$15,03717 claims
Lilly USA, LLCMounjaro$294$14,12213 claims
PfizerEliquis$104$14,11711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →